Innovation is the best medicine Built on a foundation of deep research, RTW invests with innovative companies looking to bring important new products to patients. OUR FOCUS ON INNOVATIVE MEDICINE We have developed expertise through our comprehensive study of industry and academic efforts in targeted areas of significant innovation. By focusing our energies, we believe … Home Page Read More »
Investment Type: Venture Capital
Mentions in press and media 4
| Date | Title | Description |
| 28.05.2024 | Johnson & Johnson acquires Numab spin-off for USD 1.25 billion | Numab Therapeutics AG based in Horgen (ZH) is developing multi-specific antibody-based immunotherapies for inflammation and cancer. Johnson & Johnson will acquire global rights to Numabs lead molecule NM26, a Phase 2-ready investigatio... |
| 28.02.2023 | Oricell Closes $45M Series B1 Financing to Expand Development of Key Products | SHANGHAI, Feb. 28, 2023 /PRNewswire/ -- Oricell Therapeutics Co., Ltd ("Oricell" or "the Company"), a China-based innovative pharmaceutical company committed to the development of tumor cellular immunotherapeutics, today... |
| 20.05.2021 | Numab Therapeutics Completes CHF 100 Million Series C Financing | |
| 20.05.2021 | Numab Therapeutics Completes CHF 100 Million Series C Financing | Numab Therapeutics aims to write the next chapter in cancer immunotherapy by creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. Its lead product was designed to balance potent anti-tumor immunity wit... |